2,664 Shares of AbbVie Inc. $ABBV Bought by Canandaigua National Trust Co of Florida

Canandaigua National Trust Co of Florida purchased a new position in AbbVie Inc. (NYSE:ABBV) in the third quarter, Holdings Channel reports. The fund purchased 2,664 shares of the company’s stock, valued at approximately $697,000.

Other institutional investors also recently bought and sold shares of the company. Ranch Capital Advisors Inc. grew its position in shares of AbbVie by 37.0% in the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock valued at $3,238,000 after purchasing an additional 4,017 shares during the period. Capital Advisors Inc. OK raised its position in shares of AbbVie by 11.2% during the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock worth $112,516,000 after purchasing an additional 45,132 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new position in AbbVie in the 2nd quarter valued at about $23,557,000. Wedge Capital Management L L P NC lifted its stake in AbbVie by 7.5% in the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock valued at $33,865,000 after buying an additional 9,380 shares in the last quarter. Finally, Mission Wealth Management LP boosted its holdings in AbbVie by 119.1% in the 2nd quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock worth $17,376,000 after buying an additional 37,531 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

Shares of ABBV stock traded up $4.67 during trading hours on Wednesday, reaching $271.37. The company had a trading volume of 6,075,433 shares, compared to its average volume of 6,434,720. The stock has a fifty day moving average of $258.12 and a 200-day moving average of $235.42. The company has a market capitalization of $479.44 billion, a price-to-earnings ratio of 76.66, a PEG ratio of 1.20 and a beta of 0.24. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $274.94.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts forecast that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is currently 195.48%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The FDA granted two Breakthrough Therapy Designations for AbbVie’s investigational telisotuzumab adizutecan (Temab-A/ABBV-400) in colorectal cancer and non-small cell lung cancer. The designations could accelerate development and regulatory review for the antibody-drug conjugate, strengthening AbbVie’s growing oncology pipeline. Update: AbbVie Shares Rise After FDA Gives 2 Breakthrough Designations for Cancer Drug
• Positive Sentiment: AbbVie and Genmab reported that the Epkinly (epcoritamab) plus R-CHOP combination reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The Phase 3 success supports potential expansion into frontline treatment and could improve the long-term commercial outlook for the partnership. AbbVie Cut Frontline DLBCL Progression Or Death Risk By 51%
• Positive Sentiment: Scotiabank raised its AbbVie price target from $280 to $320 and maintained a “sector outperform” rating, adding to bullish analyst sentiment around the company’s pipeline and earnings potential. AbbVie Stock Price Target Raised at Scotiabank
• Neutral Sentiment: AbbVie is scheduled to report third-quarter results later this month. Investors may remain focused on whether upcoming results and management commentary support the current premium valuation and forward growth expectations. Should You Buy AbbVie Stock Before Oct. 30?
• Negative Sentiment: AbbVie updated third-quarter 2026 EPS guidance to $3.73-$3.77, below the roughly $3.85 consensus estimate. The lower outlook may limit near-term upside and suggests investors will scrutinize operating performance despite the positive drug-development news. AbbVie Issues Q3 2026 Earnings Guidance
• Negative Sentiment: One report highlighted AbbVie’s payout ratio of about 190%, raising concerns that the dividend currently exceeds reported earnings and could face pressure if cash flow weakens. This is a longer-term risk rather than a direct change to the dividend policy. AbbVie Pays Out More Than It Earns

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have commented on ABBV shares. Royal Bank Of Canada increased their target price on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $240.00 price target (down from $250.00) on shares of AbbVie in a research report on Wednesday, September 16th. Canaccord Genuity Group raised their price objective on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a report on Monday, August 3rd. JPMorgan Chase & Co. lifted their target price on shares of AbbVie from $280.00 to $285.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Finally, Piper Sandler upped their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $274.32.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.